OBJECTIVE To perform a pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China. METHODS From the perspective of China’s healthcare system， a Markov model was constructed based on literature data regarding the treatment of cervical cancer with camrelizumab combined with chemotherapy， where the incidence of adverse reactions was obtained through a meta-analysis. The model was run over a 10-year time horizon with a 3-week cycle length. Costs included direct costs （e.g. drug cost， adverse event treatment cost）. Utility values were derived from existing studies， and transition probabilities were calculated using literature data， with a discount rate of 5%； the willingness-to-pay （WTP） threshold was set at 3 times China’s 2024 per capita gross domestic product （GDP）， i.e. 287 247 yuan/quality-adjusted life year（QALY）. Cost-effectiveness was compared between camrelizumab combined with chemotherapy and monotherapy. One-way sensitivity analysis and Monte Carlo simulation were used to evaluate the impact of parameter variations on results. RESULTS Compared with camrelizumab monotherapy， the incremental cost-effectiveness ratio （ICER） of camrelizumab combined with chemotherapy was 181 507.58 yuan/QALY， below the predefined WTP threshold. One-way sensitivity analysis showed that the outcomes were largely affected by the progression-free survival-to-death transition probabilities in both groups. Probabilistic sensitivity analysis indicated a 91.8% probability of camrelizumab combined with chemotherapy being cost-effective at a WTP threshold of 3 times China’s 2024 per capita GDP. CONCLUSIONS From China’s healthcare system perspective， camrelizumab combined with chemotherapy is cost-effective for cervical cancer in China， compared with monotherapy， when using 3 times China’s 2024 per capita GDP as the WTP threshold.